Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


510(k) average total review time drops to 157 days in first four months of FY 1996.

This article was originally published in The Gray Sheet

Executive Summary

510(K) AVERAGE TOTAL REVIEW TIME OF 162 DAYS FOR JANUARY represents a slight increase from the 157-day average for December, according to FDA's most recent figures. The total average review time, which covers the period of the agency's receipt of a premarket notification to a final decision, has fluctuated over the first four months of FY 1996 (began Oct. 1) but has remained below the average review time of 178 days in fiscal 1995 ("The Gray Sheet" Oct. 9, 1995, p. 3). Total 510(k) review time hit a low of 137 days in October and jumped to 170 days in November, averaging about 157 days for the first four months of the fiscal year overall.

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts